Ocular Therapeutix（纳斯达克代码：OCUL）报告其季度每股亏损为$(0.29)，低于分析师普遍预期的$(0.24)，差异为20.83%。与去年同期每股亏损$(0.35)相比，这一数字增加了17.14%。该公司报告季度销售额为1708万美元，低于分析师普遍预期的1720万美元，差异为0.71%。与去年同期的1480万美元销售额相比，这一数字增加了15.41%。

以上内容来自Benzinga Earnings专栏，原文如下：

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 17.14 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $17.08 million which missed the analyst consensus estimate of $17.20 million by 0.71 percent. This is a 15.41 percent increase over sales of $14.80 million the same period last year.